Nearsightedness Clinical Trials

Find Nearsightedness Clinical Trials Near You

Randomized Controlled Double Masked, Trial to Assess the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children Compared to No Treatment (DYMOND Study)

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The DYMOND study evaluates the safety and effectiveness of TrackSight™, a digital medical application designed to slow myopia (nearsightedness) progression in children during everyday screen use. TrackSight uses eye-tracking technology to keep central vision clear while subtly adjusting the image in the peripheral viewing area, based on established scientific principles known to influence eye growth. Up to 150 children aged 6 to 12 with myopia will participate at sites in Israel and Hong Kong. All participants will continue wearing their regular single-vision glasses and will be randomly assigned to use TrackSight with or without active visual adjustment for 12 months. Eye examinations and safety assessments will be conducted at the start of the study and after 6 and 12 months. The study aims to determine whether this non-invasive digital approach can safely slow myopia progression in children.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 12
Healthy Volunteers: f
View:

• Aged 6-12 years

⁃ . Diagnosed with myopia: cycloplegic spherical or spherical equivalent (SER) between -0.75D and -5.00D, astigmatism ≤ -1.50D, anisometropia \< 1.50D

• Visual acuity 20/32 or better (age-appropriate testing) in both eyes

• Interocular VA difference ≤1.00 logMAR line

• Subject in general good health and able, as per investigator decision, to comply with study visits and protocol procedures

• The subject is using digital devices for at least 1 hour/day regularly according to parental report

• Signed informed consent by legal parent/guardian and assent approval -. Currently wearing single vision refractive correction

Locations
Other Locations
Israel
Kaplan MC
RECRUITING
Rehovot
Contact Information
Primary
Oren Yehezkel, PhD
oren@nova-sight.com
972544552568
Time Frame
Start Date: 2025-12-24
Estimated Completion Date: 2027-08
Participants
Target number of participants: 150
Treatments
Experimental: TrackSight™ with active peripheral image degradation (blur)
Participants use TrackSight™ with active peripheral image degradation enabled using combination #1 during their normal screen activities. Central vision remains clear while the peripheral image is digitally modified. Standard single-vision glasses are worn at all times.
Experimental: rackSight™ with active peripheral image degradation (contrast)
Participants use TrackSight™ with active peripheral image degradation enabled using combination #2, which applies a different level or pattern of visual modification during screen use. Central vision is unaffected, and standard single-vision glasses are worn throughout the study.
Sham_comparator: TrackSight™ with the peripheral image degradation function disabled (control).
Participants use the same TrackSight™ software and device, but the peripheral image degradation feature is disabled. Screen use and standard single-vision glasses remain unchanged, serving as the control condition.
Related Therapeutic Areas
Sponsors
Leads: NovaSight

This content was sourced from clinicaltrials.gov

Similar Clinical Trials